2024-12-23 14:34:38
Author: 3Z ehf / 2023-07-22 20:49 / Source: 3Z ehf

3Z: Zebrafish mutant model reveals novel drug candidates for ADHD

REYKJAVIK,Iceland,Nov. 22,2022 -- ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD,methylphenidate,is beneficial for only a subset of patients and can cause side effects including weight loss,insomnia and hypertension. Therefore,the development of non-stimulant based therapeutics is of high importance. In a study published in the journal Neuropsychopharmacology,3Z scientists and collaborators used a uniquely powerful genetic model and unbiased drug screen to identify novel ADHD non-stimulant therapeutics. First,it was shown that when the human ADHD risk gene Latrophilin 3 was knocked-out in zebrafish,they showed a robust hyperactive behavior,consistent with ADHD. Second,it was shown that this hyperactivity can be rescued with common on-the-market ADHD therapeutics. Finally,following a large chemical screen,five novel potential therapeutics were identified. The candidates have already entered further tests. In summary,3Z introduced a genetic model of ADHD in zebrafish and identified five novel putative therapeutics. The findings offer a novel tool for understanding ADHD,suggest a novel mechanism for its etiology and identify novel candidate therapeutics.

The study can be read here: https://www.nature.com/articles/s41386-022-01505-z

3Z´s CEO Karl Karlsson has a PhD in behavioral neuroscience and is a professor in Biomedical Engineering at Reykjavik University. Karl was extensively involved in sleep research before merging the neuroscientific and engineering skillsets to high-throughputin vivodrug screening.

Discussing the significance of the findings Karl stated:

"We are extremely pleased to publish these latest data. For us it represents a stepping stone towards developing much needed therapeutics for the market,and an important validation of our screening platform - that can be used for multiple neuropsychiatric disorders"

To find out more,please visitwww.3z.isor follow onLinkedin.

CONTACT:

Karl Ægir Karlsson


karlsson@3z.is


+3548256467

Tags: Biotechnology Engineering Health Care/Hospital Mathematics) Medical/Pharmaceuticals Pharmaceuticals STEM (Science Technology

Previous:

Next:

Leave a comment

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release